Join to View Full Profile
250 25th Ave NSte 100Nashville, TN 37203
Phone+1 615-320-5090
Fax+1 615-320-1225
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 2 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jeffrey Infante, MD is an oncologist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee and Georgia. He is a Director at Sarah Cannon.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1999 - 2002
University of Florida College of MedicineClass of 1999
Certifications & Licensure
GA State Medical License 2021 - 2027
TN State Medical License 2006 - 2022
Publications & Presentations
PubMed
- Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson
Targeted Oncology. 2022-09-01 - 11 citationsTranslational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson
Targeted Oncology. 2022-07-01 - 72 citationsPhase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53.Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald Steven Falchook
Clinical Cancer Research. 2021-10-01
Press Mentions
Johnson & Johnson’s Bleximenib Combination Therapy Shows High Response Rates in Tough-to-Treat Acute Myeloid LeukemiaJune 13th, 2025- Johnson & Johnson's Dual-Targeting CAR T-cell Therapy Shows Encouraging First Results in Large B-cell LymphomaJune 13th, 2025
- New Results for Johnson & Johnson’s Bleximenib Demonstrate Promising Antileukemic Activity in Combination with Venetoclax and Azacitidine for Acute Myeloid LeukemiaJune 13th, 2025
- Join now to see all
